Speaking to EMJ from the 19th Congress of the European Hematology Association (EHA 19) meeting, Prof. Paul Richardson , Dana-Farber Cancer Institute, USA, discusses results seen from the breakthrough PANORAMA1 study, a global randomised, double-blind, placebo-controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. He outlines the primary end-point results and side effects observed, and comments on the clinical meaningfulness of these HDAC trial results. Results of sub-sets of higher risk groups are also discussed, and Prof Richardson comments on new data with ricolinostat (ACY-1215) in multiple myeloma.
Relapsed Multiple Myeloma
European Hematology Association (EHA19)
Prof. Paul Richardson
Dana-Farber Cancer Institute